LifeVantage Corp（LFVN）股票分析

AI 分析 of LifeVantage Corp (LFVN)

持有

LifeVantage Corp (LFVN) is currently not a strong buy due to its recent performance and financial indicators. The current price is $5.87, which is significantly below its 52-week high of $11.71, indicating potential for recovery but also substantial risk. The RSI is at 43.11, suggesting it is not yet oversold, and the forward P/E ratio is high at 37.45, reflecting concerns about future earnings growth. Additionally, the company reported a 23.1% revenue decline in Q4 2026, which raises red flags about its financial health. The main risk is the high short interest at 28.46%, indicating skepticism from investors about its recovery prospects. Overall, while there may be some upside potential, the current indicators suggest a cautious approach is warranted.

估值指標

LifeVantage Corp（LFVN）目前預期本益比為 37.45，5 年平均預期本益比為 15.25。

預期本益比

高估

5 年均值 P/E

15.25

目前P/E

37.45

高估

27.08

低估

3.42

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

5.38

目前EV/EBITDA

7.49

高估

8.08

低估

2.69

預期股價營收比

合理

5 年均值 P/S

0.44

目前P/S

0.45

高估

0.64

低估

0.24

Alphio AI 對 LFVN 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%LFVN

$16.23

情境價格

基

基準

基準 · 50%LFVN

$13.81

情境價格

悲

悲觀

悲觀 · 25%LFVN

$12.31

情境價格

LFVN 常見問題 —— 由 Alphio AI 解答

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

LifeVantage Corp (LFVN) is currently not a strong buy due to its recent performance and financial indicators. The current price is $5.87, which is significantly below its 52-week high of $11.71, indicating potential for recovery but also substantial risk. The RSI is at 43.11, suggesting it is not yet oversold, and the forward P/E ratio is high at 37.45, reflecting concerns about future earnings growth. Additionally, the company reported a 23.1% revenue decline in Q4 2026, which raises red flags about its financial health. The main risk is the high short interest at 28.46%, indicating skepticism from investors about its recovery prospects. Overall, while there may be some upside potential, the current indicators suggest a cautious approach is warranted.